NCT05830045View on ClinicalTrials.gov

A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

May 19, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

QLP2117

Specified dose on specified days

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY